Facing growing financial, regulatory, and research challenges, the life sciences industry continues to grow its decades-long reliance on SAS, the leader in business analytics, for breakthrough innovation.

SAS' unique data integration and advanced analytics solutions for life sciences have proven crucial for companies coping with data growth, increasingly sophisticated analytical requirements, and the growing need for cross-industry partnerships.
In the past year, SAS Clinical Data Integration adoption has more than doubled.
The solution helps improve operational efficiency while lowering cost; automation and standardisation using data aggregation for clinical trials; greater ease of use by collating information from virtually any hardware platform or operating system; and increased team productivity with standardised processes and a user-friendly graphical interface.
New SAS Clinical Data Integration customers include Astra Zeneca, Harvard Clinical, Iris, Queensland University, Sigma Tau and Take Solutions.
SAS Drug Development use grew more than 25%. The solution offers secure, centralised access to large complex data; streamlined processes enabling multiple analyses with complex project management; early visibility and quicker decisions by clinical researchers into adaptive trial designs; and shorter development cycles, reducing cost and speeding time to market.
New SAS Drug Development customers include Taisho, Merrimack Pharmaceuticals and Santen Pharmaceutical.
"Advanced analytics are critical in facilitating transformation in life sciences," says Alan Louie, research director, IDC Health Insights' Clinical Development, Strategy and Technology service.
"The advanced capabilities in SAS' solutions are a strong testament of the company's industry leadership and shows that SAS will remain a leading contributor to industry success."
For more than 34 years, life sciences companies have chosen SAS to access manage and analyse research and operational data to improve drug discovery, expedite product development, and mitigate risks.
In support of that close, historical relationship and the transformation changes underway across the industry, SAS recently formed a new team of industry experts representing pharmaceutical, clinical research, health services and payers.
The Centre for Health Analytics and Insights (CHAI) is exploring innovative applications of advanced analytics in areas such as adaptive clinical trials and showcasing how other industries have applied advanced analytics in support of business transformation.
"The need of the moment is a collaborative and comprehensive approach that uses health analytics to resolve common pains across the pharma, health plans and care delivery sectors," says CHAI MD, Jason Burke.
"We have the team – with more than 250 years of industry experience – to help transition the industry to new operating models."
Life sciences and healthcare represent one of SAS's largest business segments. SAS is the choice of 100% of the FORTUNE Global 500 life sciences companies. Eli Lilly, Daiichi Sankyo and Alcon are among the leading pharmaceutical companies that use SAS.
This news was announced at the annual meeting of the Drug Information Association (DIA) in Chicago. SAS, exhibiting in booth 1349, is participating in the event's interoperability showcase, which simulates how health information is seamlessly passed from care providers to facilitate clinical research and safety reporting.